陈忠平 职务：胶质瘤单病种首席专家
职称：教授、主任医师、博士生导师、胶质瘤首席专家
专长：脑（神经系统）肿瘤的显微外科手术和综合治疗

主要简介 详细介绍 预约挂号

一、基本情况
职称：教授、主任医师、博士生导师、胶质瘤首席专家
职务：胶质瘤单病种首席专家
专家门诊时间：周二上午；周五上午
专业特长：从事神经外科临床工作三十年，在神经外科疾病的诊断和治疗方面拥有丰富的经验。擅长脑（神经系统）各类肿瘤（包括胶质瘤，脑膜瘤，听神经瘤，垂体瘤等）的显微外科手术和综合治疗，特别是胶质瘤的个体化综合治疗和研究。
二、学习工作经历：
　1978年—1982年：苏州医学院医学系本科毕业
　1982年12月—1993年：苏州医学院附一院神经外科工作；期间在职读神经外科硕士(1989年毕业)和博士（1993年毕业）
　1993年9月—1999年9月：加拿大麦吉尔大学，神经外科博士后/Researchassociate
　1999年11月至今：中山大学附属肿瘤医院心神经外科工作

陈忠平
主任医师，博士导师，胶质瘤首席专家
1957年8月生，男，汉族，江苏江阴人
门诊时间：周二上午、周五上午
教育和工作经历
　　1982年：苏州医学院本科毕业
　　1982-1993年：苏州医学院附属第一医院神经外科 神经外科硕士（1989），神经外科博士（1993）
　　1993-1996年：加拿大McGill 大学神经外科博士后
　　1996-1999年：加拿大McGill 大学神经外科/肿瘤科Research associate
　　1999年11月-：中山大学肿瘤防治中心神经外科/神经肿瘤科主任
专业擅长
　　从事神经外科医疗、教学和科研工作三十余年，在神经外科疾病的诊断和治疗方面拥有丰富的经验。对脑（神经系统）肿瘤的显微外科手术和综合治疗具有较深的造诣，特别是脑胶质瘤的个体化综合治疗，采用包括依据肿瘤分子特征的预见性化疗、CIK细胞局部免疫治疗等使数以千计的病人获得良好的治疗效果。除了高超的临床医术之外，陈忠平教授还在基础研究方面颇有建树。在神经肿瘤分子生物学-尤其是胶质瘤耐药/放射抗拒分子机制方面做了较深入的研究,在恶性脑肿瘤免疫治疗的基础和临床应用方面也进行了探索。首先提出并用转基因试验证明，核苷酸切除修复系统中的重要因子 - ERCC2的表达与人脑肿瘤对烷化剂的耐药相关；实验和临床研究证明DNA修复基因六氧甲基鸟嘌呤DNA甲基转移酶基因(MGMT)表达影响人脑胶质瘤对氯乙基亚硝脲化疗的效果，抑制MGMT活性可为化疗增敏。还在国际上首先报道了胶质瘤也存在血管生成拟态现象（Vasculogenic Mimicry）（J Histochem Cytochem 2005,May）。发表学术论文300多篇，其中70多篇为高水平收录杂志。获包括WHO中国青年（神经科学）优秀论著奖（1993）,加拿大神经科学学会奖（Francis McNaughton Memorial Prize）（1998）和王忠诚中国神经外科医师年度奖（2006年度学术奖）等在内的国内、外多项学术奖励。入选中国名医百强榜（2014年、2016年：脑胶质瘤手术医生 Top10）。
主要社会兼职
　　1. 中国抗癌协会神经肿瘤专业委员会主任委员（2004-2012）
　　2. 广州抗癌协会神经肿瘤专业委员会主任委员 （2001-2013）
　　3. 广东省抗癌协会神经肿瘤专业委员会主任委员 （2009-2013）
　　4. 广东省神经外科学会副主任委员
　　5. Neuro-oncology 编委
　　6. Brain Tumor Pathology 编委
　　7. Neuro-oncology Practice 编委
　　8. "癌症"杂志常务编委
　　9. "中国微侵袭神经外科杂志"编委
　　10. "广东医学" 杂志编委
　　11. "中华神经外科疾病研究杂志"编委
　　12. "中华神经外科杂志"特邀审稿专家
　　13. 国家自然科学基金评审专家库专家
　　14. 卫生部全国肿瘤规范化诊疗专家委员会(颅脑肿瘤专家)
主要著作
　　1. 脑肿瘤分子外科学. 黄强 主编，陈忠平、兰青 副主编。 中国科技出版社 1998年
　　2. 胶质瘤. 黄强 、陈忠平、兰青 主编， 中国科技出版社 2000年
　　3. 神经系统肿瘤. 陈忠平主编，北京大学医学出版社, 2009年1月
　　4. 中枢神经系统常见肿瘤诊疗纲要. 陈忠平（编写组长），北京大学医学出版社, 2010年5月(第一版)，2012年9（第二版）
　　5. 神经系统肿瘤化疗手册。陈忠平、杨群英 主编，北京大学医学出版社, 2012年2月(第一版)。
代表性论文
英文：
1.Chen ZP,Malapetsa A,Marcantonio D,Mohr G,Brien S,Panasci LC.Correlation of chloroethylnitrosourea resistance with ERCC-2 expression in human tumor cell lines as determined by quantitative competitive polymerase chain reaction. Cancer Research ,1996,56: 2475-2478.
2.Chen ZP,Mohr G,Panasci LC.Correlation between GST-μgene expression and chloroethylnitrosourea resistance in human brain tumor cell lines. Acta Academicae Medicinae Suzhou,1996,2:59-64.
3.Chen ZP,Malapetsa A,Brien S,Mohr G,Panasci LC.Quantitation of ERCC-2 expression by reverse-transcription polymerase chain reaction comparison to Northern blot analysis. Anal Biochem,1997,244: 50-54.
4.Chen ZP,Malapetsa A,McQuillan A,Marcantonia D,Bello V,Mohr G,Remack J,Brent TP,Panasci LC.Evidence for nucleotide excision repair as a modifying factor of MGMT mediated innate chloroethylnitrosourea resistance in human tumor cell lines. Molecular Pharmacology,1997,52: 815-820.
5.Chen ZP,Yarosh D,Garcia Y,Tampieri D,Mohr G,Langleben A,Panasci LC.Clinical response of O6-methylguanine-DNA methyltransferase levels to 1,3-(2-chloroethyl)-1-nitrosourea chemotherapy in glioma patients.Neurosurgical Focus,1998,4(6):artical 3.
6.Chen ZP,McQuillan A,Mohr G,Panasci LC.Excision repair cross-complementing rodent repair dificiency gene2 expression and chloroethylnitrosourea resistance in human glioma cell lines. Neurosurgery,1998,42(5)1112-1119.
7.Chen ZP,Remack J,Brent TP,Mohr G,Panasci LC.Extraneuronal Monoamine Transporter Expression vis-à-vis SauCNU Cytotoxicity in Human Tumor Cell Lines.Clinical Cancer Research, 1999,5:4186-4190.
8.Chen ZP,Wang G,Huang Q,Sun ZF,Zhou LY,Wang AD,Panasci LC.Enhanced antitumor activity of SarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model. J Neuro-Oncology,1999,44:7-14.
9.Chen ZP,Pan J,Huang Q,Sun ZF,Zhou LY,Wang AD.Antitumor efficacy of SarCNU in a Human Glioma Xenograft Model expressing both MGMT and Extraneuronal Monoamine Transporter.J Neuro-Oncology,2001,51:19-24.
10.Chen ZP,Carter CA,Alley MC,Mohr G,Panasci LC.Both Extraneuronal Monoamine Transporter and O6-methylguanine-DNA Methyltransferase Expression Influence the Antitumor Efficacy of SarCNU in Human Tumor Xenografts.J Pharmacol Exp Ther,2001,296(3):712-715.
11.Wang ZM,Chen ZP,Xu ZY,Christodoulopoulos G,Bello V,Mohr G,Aloyz R,Panasci LC.In vitro evidence for homologous recombinational repair in resistance to melphalan.J Natl Cancer Inst,2001,93(19):1473-1478.
12.Pan LX,Chen ZP,Liu YS,Zhao JH.Magnetic Resonance Imaging and Biological Markers in Pituitary Adenomas with Invasion of the Cavernous Sinus Space.J Neuro-oncology,2005, 74(1):71-76.
13.Yue WY,Chen ZP.Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem.2005, 53(8):997-1002.
14.Chen HY,Shao CJ,Shi HL,Mu YG,Sai K,Chen ZP.Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-à-vis chemotherapy drug cytotoxicity in human gliomas.J Neuro-oncology,2007,82:257-262.
15.Shao CJ,Fu J,Shi HL,Mu YG,Chen ZP.Activities of DNA-PK and Ku86, but not Ku70, may predictsensitivity to cisplatin in human gliomas.J Neurooncol,2008,89(1):27-35.
16.Yue WY,Yu SH, Zhao SG,Chen ZP. Molecular markers relating to malignant progression in grade II astrocytoma. J Neurosurgery,2009,110(4):709-14.
17.Fu J, Liu ZG, Liu XM, Chen FR, Shi HL, Pang JC, Ng HK, Chen ZP,Glioblastoma stem cells resistant to temozolomide-induceautophagy.chinese medical journal,2009,122(11):1255-1259.
18.Fu J,Shao CJ,Chen FR,NG HK,Chen ZP.Autophagy Induced by Valproic Acid is Associated with Oxidative Stress in Glioma Cell Lines.Neuro-oncology,2010,12(4):328-340.
19.Chen HY,Shao CJ,Chen FR,Kwan AL,Chen ZP.Role of ERCC1 Promoter Hypermethylation in drug resistance to cisplatin in human gliomas. Int J Cancer,2010,126(8):1255-1259.
20.Liu XM,Zhang QP,Mu YG,Zhang XH,Sai K,Pang JC,Ng HK,Chen ZP.Clinical significance of vasculogenic mimicry in human gliomas. J Neurooncol,2011,(105 ):173-179.
21.Chen YS,Jing ZT,Luo C,Zhuang MH,Xia JZ,Chen ZP,Wang YJ.Vasculogenic mimicry–potential target for glioblastoma therapy:an in vitro and in vivo study.Med Oncol,2012,29:324–331.
22.Yue WY,Sai K,Wu QL,Xia YF,Yu SH,Chen ZP.Long-term molecular changes in WHO grade II astrocytomas following radiotherapy.Chin J Cancer,2012,31(3):159-165.
23.Jiang XB,Ke C,Han ZA,Lin SH,Mou YG,Luo RZ,Wu SX,Chen ZP.Intraparenchymal papillary meningioma of brainstem: case report and literature review.Jiang et al.World Journal of Surgical Oncology, 2012, 10:10.
24.Cui L,Fu J,Pang JC, Qiu ZK,Liu XM,Chen FR, Shi HL,Ng HK,Chen ZP.Overexpression of IL-7 enhances cisplatin resistance in glioma.Cancer Biology & Therapy ,2012,13 :7,496-503.
25.Shao CJ, Wu MW, Chen FR, Li C, Xia YF, Chen ZP. Histone deacetylase inhibitor, 2-propylpentanoic acid, increases the chemosensitivity and radiosensitivity of human glioma cell lines in vitro. Chin Med J, 2012;125(24):4338-4343.
26.Mu YG, Huang LJ, Li SY, Ke C, Chen Y, Jin Y, Chen ZP. Working memory and the identification of facial expression in patients with left frontal glioma. Neuro Oncol (2012) 14(suppl 4): iv81-iv89.
27.Sai K, Yang QY,Shen D,Chen ZP. Chemotherapy for gliomas in mainland China: An overview. Oncology Letters ,2013,5: 1448-1452.
28.Wang J, Sai K, Chen FR, Chen ZP.miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. Cancer Chemother Pharmacol. 2013 Jul;72(1):147-158
29.Fu J, Yang QY, Sai K, Chen FR, Pang JC, Ng HK, Kwan AL, Chen ZP.TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cells. Neuro-oncology, 2013,15（10）：1353-1365
30.Sai K, Mou YG,Zeng J, Lv YC, Xi SY, Guan S, Zhang XH,Wang J,Ke C,Guo JG, Chen YS,Chen ZP.Neurosurgical interventions for patients with nasopharyngeal carcinoma: a single institution experience. World Journal of Surgical Oncology 2013, 11:227
31.Li G, Zhang ZG, Jin TB,Liang HJ,Tu YY,Gong L, Chen zp andGao GD.High frequency of the X-chromosome inactivationin young female patients with high-grade glioma. Diagnostic Pathology 2013, 8:101.
32.Chen Y-S and Chen Z-P. Vasculogenic mimicry: a novel target for glioma therapy. Chin J Cancer; 2014; Vol. 33 Issue 2 ;74-79.
33.Qiu ZK, Shen D, Chen YS, Yang QY,Guo CC,Feng BH, Chen ZP.Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells. Chin J Cancer; 2014; Vol. 33 Issue 2 :115-122.
34.Sai K, Li WY, Chen YS, Wang J, Guan S, Yang QY, Guo CC, Mou YG, Li WP, Chen ZP. Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma. Am J Chin Med2014;42(2):485-503
35.Sai K, Zhong MG, Wang J, Chen YS, Mou YG, Ke C, Zhang XH, Yang QY, Lin FH, Guo CC, Chen ZH, Zeng J, Lv YC, Li X, Gao WC,Chen ZP. Safety evaluation of high-dose BCNU-loaded biodegradable implants in Chinese patients with recurrent malignant gliomas. J Neurol Sci. 2014 Aug 15;343(1-2):60-5. doi: 10.1016/j.jns.2014.05.022. Epub 2014 May 17.
36.Guo CC, Yang QY, Sai K，Chen ZP. Clinical Practice of Chemotherapy with Temozolomide in China. Chemotherapy: open Access,2014, 3（2）
37. Sai K, Chen ZP. What can Neurosurgeons Do for Brain Tumor Patients: 15-Year Experience at a Cancer Center. Austin J Neurosurg. 2014,1(4) :3
38.Zhang J, Sai K, Wang J, Chen YS, Yan SM, Chen ZP. Ectopic cortical anaplastic ependymoma: An unusual case report and literature review. Clin Neurol Neurosurg. 2014 Jul 2;124C:142-145.
39.Sun YC, Wang J, Guo CC, Sai K, Wang J, Chen FR, Yang QY, Chen YS, Wang J, To TS, Zhang ZP, Mu YG, Chen ZP*. MiR-181b sensitizes glioma cells to teniposide by targeting MDM2. BMC Cancer. 2014 Aug 25;14:611.
40.Qun-ying Yang, Cheng-cheng Guo, Zhong-ping. Chen. Profile of nimotuzumab in the treatment of high-grade glioma. OncoTargets and Therapy 2015:8 819–825.
41.ZE-SHUN ZHANG, JING WANG, YOU-BI SHEN, CHENG-CHENG GUO, KE SAI, FU-RONG CHEN, XIN MEI, FU HAN and ZHONG-PING CHEN. Dihydroartemisinin increases temozolomide efficacy in glioma cells by inducing autophagy.ONCOLOGY LETTERS 10: 379-383, 2015
42.Dong Shen, Cheng-cheng Guo , Jing Wang, Zhi-kun Qiu, Ke Sai , Qun-ying Yang, Yin-sheng Chen, Fu-rong Chen , Jie Wang, Lawrence Panasci, Zhong-ping Chen 。 Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells。 Oncology Reports 2015,34:2715-2721.
43.Jing Wang, Yi-ying Zhao, Jian-feng Li, Cheng-cheng Guo, Fu-rong Chen, Hong-kai Su, Hua-fu Zhao, Ya-kang Long, Jian-yong Shao, Shing-shun Tony To, Zhong-ping Chen . IDH1 mutation detection by droplet digital PCR in glioma. Oncotarget. 2015 Nov 24;6(37):39651-39660.
44.Yang QY, Guo CC, Deng ML, Wang J, Wang J, Lin FH, Zhang J, Jiang XB, Mou YG, Chen ZP. Treatment of primary intracranial germ cell tumors: Single center experience with 42 clinically diagnosed cases. Oncotarget, 2016 Sep 13;7(37):60665-60675. doi: 10.18632/oncotarget.10218.
45.Hua-Fu Zhao 1,3† , Jing Wang 1,2† , Hao-Ran Jiang 4 , Zhong-Ping Chen 2* and Shing-Shun Tony To. PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition, Journal of Experimental & Clinical Cancer Research, (2016) 35:78
46.Feng HB, Wang J, Jiang HR, Mei X, Zhao YY, Chen FR, Qu Y, Sai K, Guo CC, Yang QY, Zhang ZP, Chen ZP. β-Elemene Selectively Inhibits the Proliferation of Glioma Stem-Like Cells Through the Downregulation of Notch1. STEM CELLS T RANSLATIONAL MEDICINE , 2017;6:830–839. Published Ahead of Print on October 7, 2016 as 10.5966/sctm.2016-0009.
47.Zhang J, Zhang XH, Wang ZF, Li YP, Zhu ZQ, Sun JC, Chen ZH, Wu SY, Sai K, Wang J, Mou YG, Chen ZP. Transforaminal Resection of Cervical Dumbbell Schwannomas in Patients with Additional Tumors. World Neurosurg. World Neurosurg. 2017 Feb;98:768-773. Published online 2016 Nov 17. pii: S1878-8750(16)31185-8. doi: 10.1016/j.wneu.2016.11.037.
48.Mei X, Chen YS, Chen FR, Xi SY, Chen ZP. Glioblastoma stem cell differentiation into endothelial cells evidenced through live cell imaging Running title: Live cell imaging of GSCs CD34 expression. Neuro Oncol. 2017 Mar 8. doi: 10.1093/neuonc/nox016. [Epub ahead of print]
49.Ke C, Wang J, Xi S, Li KK, Luo J, Chen Z, Wang J, Chen ZP. An unusual combination of mirror-image dextrocardia with familial medulloblastoma : Is there a histogenetic relationship? World Neurosurg. 2017 Aug 24. pii: S1878-8750(17)31395-5. doi: 10.1016/j.wneu.2017.08.094. [Epub ahead of print]
地址：广州市东风东路651 号，邮编 510060
电话、传真：
E-Mail: chenzhp@sysucc.org.cn

更新时间：2017年10月11日